Flahy Inc. Leverages AI to Enhance Clinical Decision Support
Artificial intelligence is transforming how companies interpret biological data, facilitating advancements in drug discovery and enabling more personalized healthcare solutions. Flahy Inc., a healthcare technology firm, is applying this approach to clinical decision support, aggregating information that can significantly influence patient care, as highlighted by Jagjit Singh, the company’s founder and CEO.
Singh emphasizes the complexity of processing vast amounts of healthcare knowledge, stating, “The knowledge layer is critical because it connects your data layer to your model layer, defining what facts matter and the implications of specific data points.” Flahy utilizes a comprehensive context of biological and clinical information, structured in a graph format, to navigate decision trees that guide effective treatment choices for patients.
In a conversation with John Furrier, host of theCUBE and part of SiliconANGLE Media’s interview series, Singh discussed the pivotal role knowledge graphs play in linking patient data to facilitate personalized healthcare decisions. The exchange underscored the importance of integrating extensive medical information to make informed clinical decisions.
Harnessing Knowledge Graphs for AI-Driven Healthcare Solutions
Flahy’s team has dedicated years to developing a graph-based information database while training its machine learning models to discern relationships among various data points. Singh explained this process through a theoretical scenario involving a patient with a specific genetic mutation and a high cholesterol marker that could affect treatment options in light of new clinical findings.
“If I identify a patient with a genetic mutation and a high cholesterol marker, I need to determine if a new clinical signal will alter their treatment plan. This inherently involves a graphical question,” he elaborated. Singh also noted Flahy’s collaboration with graph technology providers, including Neo4j Inc. A significant challenge they face is incorporating data from wearable devices into their graphs, enabling the system to track health changes over time.
Singh stated, “We have created our proprietary engines specifically for these challenges.” He views clinical decision-making as a traversal problem where integrating longitudinal data into a specific graph remains crucial. Addressing this challenge will enhance the connectivity of disparate health data modalities, allowing for more accurate decision-making.
As AI-powered healthcare evolves, Singh stresses the importance of transparency in how information impacts clinical decisions. Flahy’s product, FlahyLife, integrates biological and health data to inform next steps in prevention, early detection, and treatment planning. The company collaborates with top clinical laboratories and health systems to implement its platform, which aims to enhance clinical decision-making and reduce care gaps.
Singh concluded, “By effectively connecting the graph, we can make well-reasoned decisions, ensuring that the right patients receive the appropriate tests at the optimal time.” This approach exemplifies how AI innovation can reshape the healthcare landscape, driving improved outcomes through intelligent data integration.
For a deeper understanding of Flahy’s approach and the implications of AI in healthcare, viewers can explore the complete video interview as part of theCUBE + NYSE Wired: AI Luminaries series.